FEATURED NEWS

MATEC
October 20, 2017
Perinatal Antiretroviral Treatment Guidelines Updated October 19, 2017: The Recommendations for the use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States were recently updated. The following is a summary of what's changed in this revision: Recommendations for Use of MORE
MATEC
October 20, 2017
HHS Adult and Adolescent Antiretroviral Treatment Guidelines Updated The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) has released an updated version of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Key guideline updates include the following: In the What to Start MORE
FDA
October 13, 2017
FDA Approved changes to the Sustiva label, Genvoya, Norvir, Descovy and more. On October 12, 2017 the FDA approved changed to the Sustiva (efavienz) package insert to: Update information on hepatotoxicity in DOSAGE and ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSEREACTIONS and Patient Information sections. Update CONTRAINDICATIONS and MORE
MATEC
August 17, 2017
Adult and Adolescent Opportunistic Infections Guidlines Updated The following sections of the Guidelines for the Prevemtion and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently been updated: Hepatitis B Virus infection: This section was updated to include TAF/FTC as a treatment option for patients with HBV/HIV MORE
MATEC
August 1, 2017
Adult and Adolescent Opportunistic Infections Guidelines Updated July 28, 2017: The following sections of the Guidlines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently been updated: Click here to view recently updated guidlines Sections of the Pneumocystis guidlines have been MORE
FDA
June 21, 2017
FDA approves changes to the Kaletra label FDA approved changes to the Kaletra (lopinavir/ritonavir) tablet and oral solution labels. These changes include updates to the following sections: Section 2: DOSAGE and ADMINISTRATION with information about use of the oral solution with a feeding tube. 2.1 General Administration Recommendations Because MORE
MATEC
June 1, 2017
Updates to the Tuberculosis Section of the Adult and Adolescent Opportunistic Infections Guidelines May 18, 2017: The tuberculosis (TB) section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was recently updated. In this revision, the epidemiology, diagnosis, and treatment sections MORE
MATEC
May 11, 2017
FDA Updates STRIBILD and TYBOST labels May 4, 2017 The STRIBILD and TYBOST labels were updated to include revised text regarding corticosteroids as follows: STRIBILD Section 7 Drug Interaction, Table 6 was revised for systemic, inhaled, nasal, and opthalmic corticosteroids as follows. Table 6 Established and Other Potentially Significant Drug MORE
MATEC
April 7, 2017
Adult and Adolescent Opportunistic Infections Guidelines Updated U.S. Department of Health and Human Services, April 7, 2017: The Malaria section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was recently updated. In this revision, the epidemiology and treatment sections were updated MORE
MATEC
March 24, 2017
Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV Infected Adults and Adolescents document was published in an electronic format that could be easily updated as relevant changes in prevention and MORE
MATEC
July 14, 2016
New CDC MMWR report on antibiotic-resistant gonorrhea includes concerning findings for azithromycin - one of two drugs in the only recommended treatment regimen Centers for Disease Control and Prevention (CDC), July 14, 2016. On July 14, 2016 CDC, On July 14, 2016, the Centers for Disease Control and Prevention (CDC) MMWR report titled Neisseria MORE
FDA
March 24, 2016
Update: Meningococcal Vaccine Recommendations March 18th, Chicago Department of Public Health. The Chicago Department of Public Health (CDPH) is investigating a new case of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C reported in March 2016, 9 months following the last case tied to a Chicago-area outbreak of serogroup MORE

Pages